EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Determinants of Progression and Mortality in Lymphangioleiomyomatosis

Wenshuai Xu, Chenlu Yang, Chongsheng Cheng, Yani Wang, Danjing Hu, Jiannan Huang, Yudi He, Jun Wang, Keqi Chen, Luning Yang, Wangji Zhou, Tengyue Zhang und 12 weitere

CHEST · 2023

DOI: 10.1016/j.chest.2023.02.026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CHEST, 2023. Verfasst von Wenshuai Xu und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Complex, Severe and Rare Diseases, Peking Union Medical College, Chinese …. Hauptthemen laut MEDLINE: Lymphangioleiomyomatosis, Lung Neoplasms. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Ministry of Science and Technology of the People's Republic of China, Chinese Academy of Medical Sciences & Peking Union Medical College.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Lymphangioleiomyomatosis is a progressive diffuse cystic lung disease with approximately 85% survival at 10 years. The determinants of disease progression and mortality after the introduction of sirolimus therapy and vascular endothelial growth factor D (VEGF-D) as a biomarker have not been well defined. RESEARCH QUESTION: Which factors, including VEGF-D and sirolimus therapy, influence disease progression and survival prognosis in patients with lymphangioleiomyomatosis? STUDY DESIGN AND METHODS: The progression dataset and the survival dataset included 282 and 574 patients, respectively, from Peking Union Medical College Hospital, Beijing, China. A mixed-effects model was used to compute the rate of decline in FEV1, and generalized linear models were used to identify variables affecting FEV1 decline. A Cox proportional hazards model was used to explore the association between clinical variables and the outcomes of death or lung transplantation in patients with lymphangioleiomyomatosis. RESULTS: VEGF-D levels and sirolimus treatment were associated with FEV1 changes and survival prognosis. Compared with patients with VEGF-D of < 800 pg/mL at baseline, patients with VEGF-D of ≥ 800 pg/mL lost FEV1 faster (SE, -38.86 mL/y; 95% CI, -73.90 to -3.82 mL/y; P = .031). The 8-year cumulative survival rates of patients with VEGF-D of ≥ 2,000 pg/mL and < 2,000 pg/mL were 82.9% and 95.1%, respectively (P = .014). The generalized linear regression model also demonstrated the benefit of delaying the decline of FEV1 by 65.56 mL/y (95% CI, 29.06-102.06 mL/y) in patients treated with sirolimus compared with those without sirolimus (P < .001). The 8-year risk of death was reduced by 85.1% (hazard ratio, 0.149; 95% CI, 0.075-0.299) after sirolimus treatment. After inverse treatment probability weighting, the risks of death in the sirolimus group were reduced by 85.6%. CT scan results of grade III severity were associated with worse progression than results of grades I or II severity. Patients with baseline FEV1 of 70% predicted or St. George's Respiratory Questionnaire Symptoms domain 50 or higher predicted a higher risk of worse survival. INTERPRETATION: Serum VEGF-D levels, a biomarker of lymphangioleiomyomatosis, are associated with disease progression and survival. Sirolimus therapy is associated with slower disease progression and better survival in patients with lymphangioleiomyomatosis. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT03193892; URL: www. CLINICALTRIALS: gov.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LymphangioleiomyomatosisLung NeoplasmsHumansVascular Endothelial Growth Factor DSirolimusBiomarkersDisease Progression

Stichwörter der Autor:innen

FEV(1)VEGF-Dlymphangioleiomyomatosismortalityprognosissirolimus

Substanzen

Vascular Endothelial Growth Factor DSirolimusBiomarkers

Autor:innen und Institutionen

  • Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Complex, Severe and Rare Diseases, Peking Union Medical College, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, C…
  • Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
  • Center of Medical Research, State Key Laboratory of Complex, Severe and Rare Diseases, Beijing, China.
  • Department of Pathology, Peking Union Medical College Hospital, Beijing, China.
  • Department of Radiology, Peking Union Medical College Hospital, Beijing, China.
  • Department of Physiology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.

Förderung

  • National Natural Science Foundation of China
  • Ministry of Science and Technology of the People&apos;s Republic of China
  • Chinese Academy of Medical Sciences &amp; Peking Union Medical College
  • Peking Union Medical College Hospital
  • National Key Research and Development Program of China

Zitieren

APA

Xu, W., Yang, C., Cheng, C., Wang, Y., Hu, D., Huang, J., He, Y., Wang, J., Chen, K., Yang, L., Zhou, W., Zhang, T., Liu, S., Dai, J., Meng, S., Li, X., Yang, Y., Wang, S. T., Feng, R., …, & Xu, K. F. (2023). Determinants of Progression and Mortality in Lymphangioleiomyomatosis. CHEST. https://doi.org/10.1016/j.chest.2023.02.026

Vancouver

Xu W, Yang C, Cheng C, Wang Y, Hu D, Huang J, et al. Determinants of Progression and Mortality in Lymphangioleiomyomatosis. CHEST. 2023. doi:10.1016/j.chest.2023.02.026

BibTeX
@article{Xu2023,
  author = {Xu, Wenshuai and Yang, Chenlu and Cheng, Chongsheng and Wang, Yani and Hu, Danjing and Huang, Jiannan and He, Yudi and Wang, Jun and Chen, Keqi and Yang, Luning and Zhou, Wangji and Zhang, Tengyue and Liu, Song and Dai, Jinrong and Meng, Shuzhen and Li, Xue and Yang, Yanli and Wang, Shao-Ting and Feng, Ruie and Zhang, Weihong and Zhang, Hongbing and Wang, Li and Tian, Xinlun and Xu, Kai-Feng},
  title = {Determinants of Progression and Mortality in Lymphangioleiomyomatosis},
  journal = {CHEST},
  year = {2023},
  doi = {10.1016/j.chest.2023.02.026}
}
Kostenlos starten →